Alogliptin Tablets

Vildagliptin Tablet

Therapeutic Indication

Type 2 Diabetes Mellitus
Improves glycemic control
Adjunct to diet and exercise
+91 85919 78885

Alogliptin

Tablet

Alogliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, enhancing insulin secretion and reducing glucagon release. It is prescribed for the management of type 2 diabetes mellitus.

Speciality Endocrinology | Internal Medicine
Tags DPP-4 Inhibitor | Antidiabetic
Strength
  • 6.5 mg
  • 12.5 mg
  • 25 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Alogliptin inhibits DPP-4 enzyme, prolonging incretin activity, which increases insulin release and decreases glucagon secretion in a glucose-dependent manner.

Pharmacokinetics

  • Absorption: Rapid after oral administration
  • Metabolism: Minimal hepatic metabolism
  • Elimination: Primarily renal excretion
  • Half-life: Approximately 21 hours

Side Effects

  • Nasopharyngitis
  • Headache
  • Upper respiratory tract infection
  • Rare: Pancreatitis

Contraindication

  • Hypersensitivity to Alogliptin
  • Severe renal impairment without dose adjustment

Interaction

  • Other antidiabetic agents (risk of hypoglycemia)
  • Strong CYP inducers may reduce efficacy

Warning and Precautions

  • Monitor renal function regularly
  • Discontinue if pancreatitis is suspected
  • Use with caution in hepatic impairment

Dosage

As directed by the Physician.